vs
COPT DEFENSE PROPERTIES（CDP）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是COPT DEFENSE PROPERTIES的1.1倍（$219.9M vs $197.4M），COPT DEFENSE PROPERTIES净利率更高（20.0% vs -1.0%，领先21.0%），COPT DEFENSE PROPERTIES同比增速更快（7.6% vs 2.0%），COPT DEFENSE PROPERTIES自由现金流更多（$288.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.1%）
COPT Defense Properties是一家专业房地产投资信托基金，重点投资写字楼物业，资产主要布局于华盛顿大都会区的近郊区域，核心租户为美国政府及国防军工行业企业。截至2024年12月31日，公司旗下共持有164栋写字楼，总面积达1650万平方英尺，同时运营31个单租户数据中心，总面积590万平方英尺。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CDP vs OFIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.4M | $219.9M |
| 净利润 | $39.4M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 19.9% | 0.2% |
| 净利率 | 20.0% | -1.0% |
| 营收同比 | 7.6% | 2.0% |
| 净利润同比 | 8.0% | 92.4% |
| 每股收益（稀释后） | $0.32 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $197.4M | $219.9M | ||
| Q3 25 | $188.8M | $205.6M | ||
| Q2 25 | $189.9M | $203.1M | ||
| Q1 25 | $187.9M | $193.6M | ||
| Q4 24 | $183.4M | $215.7M | ||
| Q3 24 | $189.2M | $196.6M | ||
| Q2 24 | $187.3M | $198.6M | ||
| Q1 24 | $193.3M | $188.6M |
| Q4 25 | $39.4M | $-2.2M | ||
| Q3 25 | $43.7M | $-22.8M | ||
| Q2 25 | $40.2M | $-14.1M | ||
| Q1 25 | $36.2M | $-53.1M | ||
| Q4 24 | $36.5M | $-29.1M | ||
| Q3 24 | $37.4M | $-27.4M | ||
| Q2 24 | $36.4M | $-33.4M | ||
| Q1 24 | $33.7M | $-36.0M |
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | 19.9% | 0.2% | ||
| Q3 25 | 22.5% | -8.3% | ||
| Q2 25 | 21.0% | -7.9% | ||
| Q1 25 | 19.1% | -25.2% | ||
| Q4 24 | 19.7% | -5.3% | ||
| Q3 24 | 19.8% | -9.6% | ||
| Q2 24 | 19.4% | -12.5% | ||
| Q1 24 | 17.5% | -15.6% |
| Q4 25 | 20.0% | -1.0% | ||
| Q3 25 | 23.2% | -11.1% | ||
| Q2 25 | 21.1% | -6.9% | ||
| Q1 25 | 19.3% | -27.4% | ||
| Q4 24 | 19.9% | -13.5% | ||
| Q3 24 | 19.8% | -13.9% | ||
| Q2 24 | 19.4% | -16.8% | ||
| Q1 24 | 17.4% | -19.1% |
| Q4 25 | $0.32 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.57 | ||
| Q2 25 | $0.34 | $-0.36 | ||
| Q1 25 | $0.31 | $-1.35 | ||
| Q4 24 | $0.31 | $-0.76 | ||
| Q3 24 | $0.32 | $-0.71 | ||
| Q2 24 | $0.31 | $-0.88 | ||
| Q1 24 | $0.29 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $275.0M | $82.0M |
| 总债务越低越好 | $2.8B | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $4.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.83× | — |
8季度趋势，按日历期对齐
| Q4 25 | $275.0M | $82.0M | ||
| Q3 25 | $23.7M | $62.9M | ||
| Q2 25 | $21.3M | $65.6M | ||
| Q1 25 | $24.3M | $58.0M | ||
| Q4 24 | $38.3M | $83.2M | ||
| Q3 24 | $34.5M | $30.1M | ||
| Q2 24 | $100.4M | $26.4M | ||
| Q1 24 | $123.1M | $27.0M |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.4B | $157.2M | ||
| Q2 25 | $2.4B | $157.0M | ||
| Q1 25 | $2.4B | $156.9M | ||
| Q4 24 | $2.4B | $157.0M | ||
| Q3 24 | $2.4B | $118.5M | ||
| Q2 24 | $2.4B | $118.0M | ||
| Q1 24 | $2.4B | $118.2M |
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.5B | $442.5M | ||
| Q2 25 | $1.5B | $458.3M | ||
| Q1 25 | $1.5B | $458.3M | ||
| Q4 24 | $1.5B | $503.1M | ||
| Q3 24 | $1.5B | $525.9M | ||
| Q2 24 | $1.5B | $546.0M | ||
| Q1 24 | $1.5B | $570.3M |
| Q4 25 | $4.7B | $850.6M | ||
| Q3 25 | $4.4B | $832.6M | ||
| Q2 25 | $4.3B | $837.2M | ||
| Q1 25 | $4.3B | $823.1M | ||
| Q4 24 | $4.3B | $893.3M | ||
| Q3 24 | $4.2B | $867.9M | ||
| Q2 24 | $4.2B | $882.0M | ||
| Q1 24 | $4.2B | $906.0M |
| Q4 25 | 1.83× | — | ||
| Q3 25 | 1.62× | 0.36× | ||
| Q2 25 | 1.63× | 0.34× | ||
| Q1 25 | 1.62× | 0.34× | ||
| Q4 24 | 1.60× | 0.31× | ||
| Q3 24 | 1.61× | 0.23× | ||
| Q2 24 | 1.61× | 0.22× | ||
| Q1 24 | 1.63× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $309.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $288.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 146.4% | 7.6% |
| 资本支出强度资本支出/营收 | 10.7% | 4.9% |
| 现金转化率经营现金流/净利润 | 7.87× | — |
| 过去12个月自由现金流最近4个季度 | $501.5M | $-1.3M |
8季度趋势，按日历期对齐
| Q4 25 | $309.9M | $27.7M | ||
| Q3 25 | $68.6M | $12.4M | ||
| Q2 25 | $87.9M | $11.6M | ||
| Q1 25 | $72.1M | $-18.4M | ||
| Q4 24 | $331.0M | $23.7M | ||
| Q3 24 | $65.1M | $11.7M | ||
| Q2 24 | $93.8M | $9.0M | ||
| Q1 24 | $71.0M | $-18.6M |
| Q4 25 | $288.9M | $16.8M | ||
| Q3 25 | $62.9M | $2.5M | ||
| Q2 25 | $84.5M | $4.5M | ||
| Q1 25 | $65.1M | $-25.1M | ||
| Q4 24 | $299.6M | $15.2M | ||
| Q3 24 | $61.0M | $6.3M | ||
| Q2 24 | $88.4M | $-360.0K | ||
| Q1 24 | $57.9M | $-29.1M |
| Q4 25 | 146.4% | 7.6% | ||
| Q3 25 | 33.3% | 1.2% | ||
| Q2 25 | 44.5% | 2.2% | ||
| Q1 25 | 34.7% | -13.0% | ||
| Q4 24 | 163.3% | 7.0% | ||
| Q3 24 | 32.3% | 3.2% | ||
| Q2 24 | 47.2% | -0.2% | ||
| Q1 24 | 30.0% | -15.4% |
| Q4 25 | 10.7% | 4.9% | ||
| Q3 25 | 3.0% | 4.8% | ||
| Q2 25 | 1.8% | 3.5% | ||
| Q1 25 | 3.7% | 3.5% | ||
| Q4 24 | 17.1% | 4.0% | ||
| Q3 24 | 2.1% | 2.7% | ||
| Q2 24 | 2.9% | 4.7% | ||
| Q1 24 | 6.8% | 5.6% |
| Q4 25 | 7.87× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 9.08× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 2.58× | — | ||
| Q1 24 | 2.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDP
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
